117 related articles for article (PubMed ID: 2612569)
1. Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents.
Hock FJ; Gerhards HJ; Wiemer G; Stechl J; Rüger W; Urbach H
Eur J Pharmacol; 1989 Nov; 171(1):79-85. PubMed ID: 2612569
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
4. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
Bünning P
Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
[TBL] [Abstract][Full Text] [Related]
6. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Metzger H; Maier R; Sitter C; Stern HO
Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Teetz V; Geiger R; Henning R; Urbach H
Arzneimittelforschung; 1984; 34(10B):1399-401. PubMed ID: 6097264
[TBL] [Abstract][Full Text] [Related]
9. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Felder K; Witte PU
Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
[TBL] [Abstract][Full Text] [Related]
10. Effect of peptidase inhibitors on [Met5]enkephalin-Arg6-Phe7 and [Met5]enkephalin-Arg6-Gly7-Leu8-induced antinociception.
Mellstrom B; Iadarola MJ; Costa E
Eur J Pharmacol; 1987 Jan; 133(2):185-90. PubMed ID: 2949992
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
[TBL] [Abstract][Full Text] [Related]
12. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine.
Hajdú P; Schmidt D; Bomm M; Hack L; Keller A
Arzneimittelforschung; 1984; 34(10B):1431-5. PubMed ID: 6097270
[TBL] [Abstract][Full Text] [Related]
13. Effects of N-[2-(1-azabicyclo[3,3,0]octan-5-yl)ethyl]2-nitroaniline fumarate (SK-946), a novel cognition activator, on learning and memory in rodent models.
Suzuki T; Hirooka K; Kanda K; Hirooka H; Furusawa K
Biol Pharm Bull; 1998 Jul; 21(7):698-703. PubMed ID: 9703252
[TBL] [Abstract][Full Text] [Related]
14. Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats.
Sakurai T; Ojima H; Yamasaki T; Kojima H; Akashi A
Jpn J Pharmacol; 1989 May; 50(1):47-53. PubMed ID: 2724699
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Met5-enkephalin-Arg6-Phe7 degradation by inhibitors of dipeptidyl carboxypeptidase.
Mellstrom B; Iadarola MJ; Yang HY; Costa E
J Pharmacol Exp Ther; 1986 Oct; 239(1):174-8. PubMed ID: 2945003
[TBL] [Abstract][Full Text] [Related]
16. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
Caspritz G; Alpermann HG; Schleyerbach R
Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
[TBL] [Abstract][Full Text] [Related]
17. Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril.
Donaubauer HH; Mayer D
Arzneimittelforschung; 1988 Jan; 38(1):14-20. PubMed ID: 2966628
[TBL] [Abstract][Full Text] [Related]
18. KC 9172 (free base of KC 7218)--an antipsychotic/anxiolytic compound. I. Antipsychotic and anxiolytic activity in comparison with chlorpromazine, clozapine, diazepam and buspirone.
Ruhland M; Krähling H; Fuchs A; Schön U
Pharmacopsychiatry; 1988 Nov; 21(6):396-8. PubMed ID: 2907649
[No Abstract] [Full Text] [Related]
19. Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice.
Botton PH; Costa MS; Ardais AP; Mioranzza S; Souza DO; da Rocha JB; Porciúncula LO
Behav Brain Res; 2010 Dec; 214(2):254-9. PubMed ID: 20553765
[TBL] [Abstract][Full Text] [Related]
20. DAU 6215, a novel 5-HT3-receptor antagonist, selectively antagonizes scopolamine-induced deficit in a passive-avoidance task, but not scopolamine-induced hypermotility in rats.
Brambilla A; Ghiorzi A; Pitsikas N; Borsini F
J Pharm Pharmacol; 1993 Sep; 45(9):841-3. PubMed ID: 7903377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
